$LRMR
Larimar Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024119100 Filed on October 30, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.345M
YoY Change 15.87%
% of Gross Profit
Research & Development $13.92M
YoY Change 111.37%
% of Gross Profit
Depreciation & Amortization $74.00K
YoY Change -7.5%
% of Gross Profit
Operating Expenses $18.26M
YoY Change 76.65%
Operating Profit -$18.26M
YoY Change 76.65%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $2.765M
YoY Change 116.86%
Pretax Income -$15.50M
YoY Change 71.07%
Income Tax
% Of Pretax Income
Net Earnings -$15.50M
YoY Change 71.0%
Net Earnings / Revenue
Basic Earnings Per Share -$0.24
Diluted Earnings Per Share -$0.24
COMMON SHARES
Basic Shares Outstanding 63.81M 63.81M
Diluted Shares Outstanding 63.81M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $203.7M
YoY Change 113.1%
Cash & Equivalents $35.07M
Short-Term Investments $168.6M
Other Short-Term Assets $8.606M
YoY Change 196.76%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $213.3M
YoY Change 116.55%
LONG-TERM ASSETS
Property, Plant & Equipment $779.0K
YoY Change 29.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $621.0K
YoY Change -2.05%
Total Long-Term Assets $5.765M
YoY Change 5.35%
TOTAL ASSETS
Total Short-Term Assets $213.3M
Total Long-Term Assets $5.765M
Total Assets $219.0M
YoY Change 110.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.686M
YoY Change 123.02%
Accrued Expenses $13.57M
YoY Change 166.45%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.29M
YoY Change 148.32%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $4.336M
YoY Change -7.74%
Total Long-Term Liabilities $4.336M
YoY Change -7.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.29M
Total Long-Term Liabilities $4.336M
Total Liabilities $20.62M
YoY Change 83.46%
SHAREHOLDERS EQUITY
Retained Earnings -$240.3M
YoY Change 36.85%
Common Stock $438.4M
YoY Change 63.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $198.4M
YoY Change
Total Liabilities & Shareholders Equity $219.0M
YoY Change 110.69%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$15.50M
YoY Change 71.0%
Depreciation, Depletion And Amortization $74.00K
YoY Change -7.5%
Cash From Operating Activities -$24.55M
YoY Change 166.8%
INVESTING ACTIVITIES
Capital Expenditures $62.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $27.33M
YoY Change -158.87%
Cash From Investing Activities $27.27M
YoY Change -158.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 30.00K
YoY Change 0.0%
NET CHANGE
Cash From Operating Activities -24.55M
Cash From Investing Activities 27.27M
Cash From Financing Activities 30.00K
Net Change In Cash 2.756M
YoY Change -104.96%
FREE CASH FLOW
Cash From Operating Activities -$24.55M
Capital Expenditures $62.00K
Free Cash Flow -$24.61M
YoY Change 167.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001374690
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36510
dei Entity Registrant Name
EntityRegistrantName
LARIMAR THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-3857670
dei Entity Address Address Line1
EntityAddressAddressLine1
Three Bala Plaza East
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 506
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19004
dei Entity Address City Or Town
EntityAddressCityOrTown
Bala Cynwyd
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei City Area Code
CityAreaCode
844
dei Local Phone Number
LocalPhoneNumber
511-9056
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
LRMR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
63806628
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35067000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26749000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
168640000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
60041000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9549000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3385000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
213256000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
90175000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
779000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
684000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3026000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3078000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1339000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1339000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
621000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
659000
CY2024Q3 us-gaap Assets
Assets
219021000
CY2023Q4 us-gaap Assets
Assets
95935000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1686000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1283000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13573000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7386000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1026000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
837000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
16285000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9506000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4336000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4709000
CY2024Q3 us-gaap Liabilities
Liabilities
20621000
CY2023Q4 us-gaap Liabilities
Liabilities
14215000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
63806628
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63806628
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43909069
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43909069
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
64000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
43000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
438312000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
270150000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-240334000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-188554000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
358000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
81000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
198400000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
81720000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
219021000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95935000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13919000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6585000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46540000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17022000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4345000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3754000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13057000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10574000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
18264000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
10339000
us-gaap Operating Expenses
OperatingExpenses
59597000
us-gaap Operating Expenses
OperatingExpenses
27596000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18264000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10339000
us-gaap Operating Income Loss
OperatingIncomeLoss
-59597000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27596000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2765000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1275000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7817000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3640000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-15499000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9064000
us-gaap Net Income Loss
NetIncomeLoss
-51780000
us-gaap Net Income Loss
NetIncomeLoss
-23956000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.86
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63806158
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63806158
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43903738
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43903738
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60399697
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60399697
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43899670
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43899670
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-15499000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9064000
us-gaap Net Income Loss
NetIncomeLoss
-51780000
us-gaap Net Income Loss
NetIncomeLoss
-23956000
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
508000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-5000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
277000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
38000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
508000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-5000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
277000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
38000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14991000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9069000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-51503000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23918000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
81720000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
161756000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2128000
CY2024Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-106000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-14654000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
230844000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2301000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11000
CY2024Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-125000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-21627000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
211404000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1957000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
30000
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
508000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-15499000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
198400000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
110903000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1833000
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
31000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6526000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
106241000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2043000
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
12000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8366000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
99930000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1821000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
24000
CY2023Q3 lrmr Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
6000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-5000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9064000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
92712000
us-gaap Profit Loss
ProfitLoss
-51780000
us-gaap Profit Loss
ProfitLoss
-23956000
us-gaap Share Based Compensation
ShareBasedCompensation
6386000
us-gaap Share Based Compensation
ShareBasedCompensation
5697000
lrmr Cash And Non Cash Operating Lease Expense
CashAndNonCashOperatingLeaseExpense
-132000
lrmr Cash And Non Cash Operating Lease Expense
CashAndNonCashOperatingLeaseExpense
-58000
us-gaap Depreciation
Depreciation
241000
us-gaap Depreciation
Depreciation
230000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-4074000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-1210000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6164000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
579000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
403000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-930000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
6137000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3314000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-38000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-4000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48945000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24116000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
336000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
189248000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
66268000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
85000000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
102250000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-104584000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
35982000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
161806000
lrmr Proceeds From Stock Options And Warrant Exercises
ProceedsFromStockOptionsAndWarrantExercises
41000
lrmr Proceeds From Stock Options And Warrant Exercises
ProceedsFromStockOptionsAndWarrantExercises
30000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
161847000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8318000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11896000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28088000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28164000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36406000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
40060000
lrmr Offering Costs Included In Accounts Payable And Accrued Expense
OfferingCostsIncludedInAccountsPayableAndAccruedExpense
50000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
465000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
452000
us-gaap Net Income Loss
NetIncomeLoss
-51800000
us-gaap Net Income Loss
NetIncomeLoss
-24000000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-240300000
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
203700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel and outside vendors to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expense, the recording as prepaid expense of payments made in advance of the actual provision of goods or services, valuation of stock-based awards and valuation of leases. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions.</span></p>
CY2024Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
31338000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
168640000
CY2024Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
199978000
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
24701000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
60041000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
84742000
CY2024Q3 us-gaap Interest Receivable
InterestReceivable
900000
CY2023Q4 us-gaap Interest Receivable
InterestReceivable
300000
CY2024Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2024Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
168282000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
358000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
168640000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
59960000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
81000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
60041000
CY2024Q3 lrmr Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
8192000
CY2023Q4 lrmr Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
1994000
CY2024Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
943000
CY2023Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
332000
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
43000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
682000
CY2024Q3 lrmr Other Prepaid Expense And Other Current Assets
OtherPrepaidExpenseAndOtherCurrentAssets
371000
CY2023Q4 lrmr Other Prepaid Expense And Other Current Assets
OtherPrepaidExpenseAndOtherCurrentAssets
377000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9549000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3385000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2245000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1909000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1466000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1225000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
779000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
684000
CY2024Q3 lrmr Depreciation Expense Excluding Leased Assets
DepreciationExpenseExcludingLeasedAssets
100000
lrmr Depreciation Expense Excluding Leased Assets
DepreciationExpenseExcludingLeasedAssets
200000
CY2023Q3 lrmr Depreciation Expense Excluding Leased Assets
DepreciationExpenseExcludingLeasedAssets
100000
lrmr Depreciation Expense Excluding Leased Assets
DepreciationExpenseExcludingLeasedAssets
200000
lrmr Depreciation Expenses Related To Sublet Assets
DepreciationExpensesRelatedToSubletAssets
100000
CY2024Q3 lrmr Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
10329000
CY2023Q4 lrmr Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
4594000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2377000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2365000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
867000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
427000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13573000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7386000
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
63806628
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63806628
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders.
CY2024Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0412
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M19D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.96
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4273502
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.06
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2082377
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.22
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
6967
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.92
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
57088
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
10.08
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6291824
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.79
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7400000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2921508
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.63
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1700000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6291824
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.79
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y9M18D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
7400000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1957000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1821000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6386000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5697000
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y8M12D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y6M
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.11
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.11
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
383000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1543000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1473000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1267000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1189000
CY2024Q3 lrmr Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
959000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6814000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1452000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
5362000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-119100-index-headers.html Edgar Link pending
0000950170-24-119100-index.html Edgar Link pending
0000950170-24-119100.txt Edgar Link pending
0000950170-24-119100-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
lrmr-20240930.htm Edgar Link pending
lrmr-20240930.xsd Edgar Link pending
lrmr-ex31_1.htm Edgar Link pending
lrmr-ex31_2.htm Edgar Link pending
lrmr-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
lrmr-20240930_htm.xml Edgar Link completed
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending